Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

3023 - Interim Results from a Phase 1 First-in-Human study of flotetuzumab, a CD123 x CD3 bispecific DART molecule, in AML/MDS


10 Sep 2017


Haematological malignancies


Norbert Vey


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


N. Vey1, J. Davidson-Moncada2, G.L. Uy3, M. Foster4, D. Rizzieri5, J. Godwin6, M. Topp7, F. Ciceri8, M. Carrabba8, G. Martinelli9, G.A. Huls10, A. Wegener11, M. Shannon2, K. Tran12, J. Sun13, E. Bonvini14, B. Löwenberg15, J. Wigginton2, J.F. Dipersio3

Author affiliations

  • 1 Département D’hématologie, Institut Paoli-Calmettes, 13009 - Marseille/FR
  • 2 Clinical Development, MacroGenics, Inc., 20850 - Rockville/US
  • 3 Division Of Oncology, Washington University School of Medicine, 63110 - St. Louis/US
  • 4 Division Of Hematology/oncology, UNC Lineberger Comprehensive Cancer Center, 27599 - Chapel Hill/US
  • 5 Hematology/oncology, Duke University Medical Center, 27522 - Durham/US
  • 6 Division Of Hematology/oncology, Providence Cancer Center, 97213 - Portland/US
  • 7 Division Of Hematology/oncology, Universitätsklinikum Würzburg, 97080 - Wurzburg/DE
  • 8 Department Of Hematology, University Vita-Salute San Raffaele, 20132 - Milano/IT
  • 9 Department Of Hematology, Policlinico Sant'Orsola-Malpighi, 40138 - Bologna/IT
  • 10 Department Of Hematology, University Medical Center Groningen, 9713GZ - Groningen/NL
  • 11 Clinical Development, Servier, Paris/FR
  • 12 Clinical Operations, MacroGenics, Inc., 20850 - Rockville/US
  • 13 Biostatistics, MacroGenics, Inc., 20850 - Rockville/US
  • 14 Research, MacroGenics, Inc., 20850 - Rockville/US
  • 15 Department Of Hematology, Erasmus University Medical Center, 3000CA - Rotterdam/NL


Abstract 3023


Acute myeloid leukemia (AML) CD34+, CD38- cells highly express CD123, associated with high-risk disease and disease progression. CD123 expression on normal HSC is negligible, enabling a promising strategy of preferential ablation with a CD123-targeted approach. Flotetuzumab (MGD006/S80880), a novel CD123 x CD3 bispecific DART protein, is designed to target CD123+ cells for elimination by T cells.


The Ph 1 dose-escalation study will define the safety profile, maximum tolerated dose and schedule (MTDS), and preliminary anti-leukemic activity of flotetuzumab. Relapsed/refractory (R/R) AML or intermediate-2/high-risk MDS will be treated with 28 day cycles of continuous infusion at doses from 3 to 1000 ng/kg/day. During C1W1, patients receive a lead-in dose (LID) of 30 ng/kg/day for 3 days followed by 100 ng/kg/day for 4 days. During C1W2-4, patients receive the cohort target dose (300-1000ng/kg/day) on either a 4-day on/3-day off or a continuous 7-day on weekly schedule. At Cycle 2 and beyond, patients are treated on a 4-day on/3-day off schedule at the cohort target dose for a maximum of 12 cycles, 2 cycles after a CR, DLT or DP. Cohort expansion will enroll 24 AML and 24 MDS patients at the MTDS. Disease status is assessed by IWG criteria.


Patients with R/R AML/MDS (35/3) have been treated with flotetuzumab, up to a dose of 500ng/kg/day. Flotetuzumab has demonstrated acceptable tolerability to date, with no MTDS yet defined for either schedule. The most common drug-related adverse event was infusion-related reaction/cytokine-release syndrome (29/38, 76% any grade; 3/38, 8% G3). Drug-related adverse events ≥G3 were observed in 14/38 (36%) of patients overall. A LID strategy and early use of tocilizumab ameliorated this toxicity and limits corticosteroid use. At 500ng/kg/day, anti-leukemic activity has been observed in 4/8 patients treated, including CRi (n = 2), morphologic leukemia free state (n = 1) and bone marrow blast reduction >50% (n = 1).


To date flotetuzumab has an acceptable safety profile and demonstrated early evidence of anti-leukemic activity.

Clinical trial identification


Legal entity responsible for the study

MacroGenics, Inc.


MacroGenics, Inc. Servier


N. Vey: Amgen, Celgene, Bristol-Myers Squib, Novartis, Servier. J. Davidson-Moncada: MacroGenics, Inc. M. Foster: Celgene MacroGenics. D. Rizzieri: Novartis, Abbvie, Pfizer, Teva, Incyte, Celgene, Gilead, Seattle Genetic, Millenium (spouse). J. Godwin: Bristol-Myers Squib, AbbVie. M. Topp: Amgen, Roche, Regeneron. G. Martinelli: Novartis, Bristol-Myers Squib, Celgene - speaker bureau Ariad/Incyte, Pfizer, Roche, MSD, Celgene – consultant. A. Wegener: Servier. M. Shannon, K. Tran, J. Sun, E. Bonvini: MacroGenics. J. Wigginton: Employee of MacroGenics. Receive salary, stock/options. J.F. Dipersio: Magenta, Celegen, Bioline, Vasculox, Cellworks, Rivervest, Hemedicus, DAVA oncology, Bristol-Myers Squib, Asteria, Amphivena, Bluebird. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.